Rate of Cancer During Pregnancy Lower Than Expected
the Cancer Therapy Advisor take:
The number of observed cancer cases during pregnancy was lower than predicted for all types, according to an article published online in the journal Cancer.
The study was register-based and used data from the Swedish Multi-Generation Register and the National Cancer Register from 1963 to 2007. The women were assessed at seven time periods: pregnancy, the three trimesters, 0-6 months, 7-12 months, and 2 years postpartum.
In the study, pregnancy-associated cancer (PAC) was determined to be a malignancy detected during pregnancy or within 2 years postpartum.
Results showed that the most common PACs were melanoma (n = 232), breast cancer (n = 139) and cervical cancer (n = 139).
The overall number of cancer cases during pregnancy was lower than expected by the study for all types of cancer, with the observed versus the expected (O/E) ratio of 0.46 (95% CI: 0.43, 0.49).
Throughout the windows of 0-6 months, 7-12 months, and the second year after delivery, the O/E ratio was close to 1 (0.93; 95% CI: 0.88, 0.98; 0.96; 95% CI: 0.91, 1.01; and 0.95; 95% CI: 0.92, 0.99, respectively).
All sites had a lower than expected rate of PAC, which could not be completely explained by delayed diagnosis. A rebound in the number of cancer cases after pregnancy was limited to melanoma, nervous system malignancies, breast cancer, and thyroid cancer.
The number of observed cancer cases during pregnancy was lower than predicted for all types.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer